New EMA website increases public access to safety data
Transparency remains the buzzword in the European pharmacovigilance legislation changes. A new website has been launched by the EMA which will feature the publication of suspected side effects in Europe that feeds from Eudravigilance. This demonstrates the ongoing attempts at increasing transparency in the safety monitory and reporting of medicines in Europe.
On the website, the public have access to suspected ADRs of medicines approved through the centralised authorisation procedure.